Health

NHS A&E opt-out testing has identified about 1,900 previously undiagnosed HIV cases since 2022

NHS England’s opt‑out A&E blood‑borne virus testing has identified about 1,900 undiagnosed HIV cases since April 2022; independent analysis and funding back the scheme.

#hiv, #nhs, #publichealth, #testing

FDA Expands IBRANCE Approval for Maintenance Treatment in HR+, HER2+ Metastatic Breast Cancer

FDA expands use of Pfizer’s IBRANCE (palbociclib) as maintenance therapy with trastuzumab and endocrine therapy for HR+, HER2+ metastatic breast cancer.

$PFE, #oncology, #breastcancer, #fda, #pharma

Open-source AI improved doctors' rare-disease diagnoses in trial — but increased high-confidence errors

Preprint: open-source model RaDaR raised physicians’ rare-disease diagnostic accuracy by 21.4 points in a randomized case-based trial — but produced more high-confidence errors.

#ai, #raredisease, #diagnosis, #medicalai

Millions Lose Marketplace Coverage and Pay More After Boosted ACA Subsidies Lapse

Six months after enhanced ACA subsidies ended, enrollment and payment data show millions lost coverage and many who kept plans face much higher costs.

#healthcare, #aca, #insurance, #enrollment

Pfizer’s Phase 3 Lung Cancer Drug Misses Overall Survival Goal; Stronger Trend in Second‑Line Patients

Pfizer's Phase 3 lung cancer trial of sigvotatug vedotin missed its overall survival goal; company sees a stronger trend in second‑line patients.

$PFE, #pfizer, #oncology, #lungcancer, #clinicaltrials

Final UN/EU/World Bank RDNA: Gaza’s health system needs $10.03 billion to rebuild; 14% of workforce lost

A joint UN/EU/World Bank assessment estimates $10.03B needed over five years to rebuild Gaza’s health system and reports 14% of health workers lost.

#gaza, #healthcare, #un, #worldbank

NHS data shows UK-trained and prioritised applicants filled 98% of 2026 specialty training posts

NHS England: 98% of 2026 specialty training posts went to UK graduates or other priority groups after the new prioritisation law took effect.

#nhs, #medical-training, #prioritisation, #uk-health

Intellia’s one-time CRISPR therapy cuts hereditary angioedema attacks 87% in Phase 3; rolling FDA filing started

Phase 3 trial of Intellia's one-time in‑vivo CRISPR therapy lonvo‑z cut hereditary angioedema attacks 87%; company began rolling FDA filing.

$NTLA, #crispr, #geneediting, #biotech, #hereditaryangioedema, #intellia

UK to spend nearly £30m to expand AI diagnostics in the NHS; £20m to roll out chest X‑ray tools to trusts by 2029

UK to invest almost £30m to expand AI-assisted diagnostics in the NHS, including £20m to roll out AI chest X-ray tools to all English trusts by 2029.

#nhs, #ai, #healthcare, #lungcancer

Largest Bundibugyo Ebola Outbreak on Record Reaches 534 Confirmed Cases, Spreads to Uganda

The Bundibugyo ebolavirus outbreak has reached 534 confirmed cases across DRC and Uganda, straining responders where no licensed vaccines or treatments exist.

#ebola, #drc, #uganda, #publichealth, #outbreak

U.S. Measles Cases Top 2,000 by Early June as 2026 Approaches Last Year’s Total

CDC reports 2,030 confirmed measles cases as of June 4, 2026, raising concerns about outbreaks, vaccination gaps and importation risks.

#measles, #vaccination, #cdc, #publichealth

UK Phase I trial finds AI-designed coronavirus vaccine candidate safe and elicits cross-reactive immune responses

Phase I UK trial: an AI-designed DNA vaccine for sarbecoviruses was safe in 39 adults and induced cross-reactive immune responses, but not proof it protects.

#covid-19, #vaccine, #clinicaltrials, #ai

Lancet warns lack of rapid test hampers response to Bundibugyo Ebola in DRC and Uganda

Lancet Comment: no reliable rapid test for Bundibugyo Ebola is delaying isolation, testing and contact tracing during the DRC–Uganda outbreak.

#ebola, #bundibugyo, #diagnostics, #drcongo, #uganda

Pfizer’s BRAFTOVI Combo Shows Longer Progression-Free Survival in First-Line BRAF V600E Metastatic Colorectal Cancer

Phase 3 BREAKWATER Cohort 3 data show encorafenib plus cetuximab with FOLFIRI extended median PFS to 15.2 months vs. 8.3 months in control.

$PFE, #oncology, #colorectalcancer, #pfizer, #braftovi

Interim phase 3: Sacituzumab tirumotecan plus pembrolizumab improves PFS in PD-L1–positive advanced NSCLC

Interim phase 3 data: adding sacituzumab tirumotecan to pembrolizumab improved progression-free survival versus pembrolizumab alone in PD‑L1+ advanced NSCLC; OS immature, toxicity higher.

$MRK, #lungcancer, #pembrolizumab, #sacituzumabtirumotecan, #clinicaltrials